Journal of Clinical Oncology
Articles in this Issue
Machine-learning prediction of 30-, 90-, and 180-day readmissions in head and neck cancer using a national readmission database.
e18089 Background: Readmissions impose major burdens on head and neck cancer (HNC) care. We employed the national readmission database(NRD) to develop and...
Genome-wide association study of neurocognitive outcomes among childhood cancer survivors.
10063 Background: Long-term survivors of childhood cancer experience heightened risk of late effects, with about 40% developing cognitive impairment. Esta...
Exploring DORIS: A cancer-focused AI knowledge platform for diagnosis and treatment information.
9035 Background: Clinicians in oncology have high demands on their time due to lack of sufficient staffing, leading to the need to work additional hours o...
A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.
8007 Background: ZG006 is a trispecific T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3, designed to...
TREM-1 upregulation as a potential predictive immune biomarker of pathologic complete response (pCR) in patients (pts) with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (NAT).
e12632 Background: There are no approved biomarkers to predict pCR after NAT based on the KEYNOTE-522 (KN-522) regimen for pts with TNBC. The tumor immune...
Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia.
6543 Background: Brexu-cel is a CD19 CAR T cell approved for adult patients with R/R B-cell ALL. We aimed to evaluate toxicity/efficacy in adult pts with...
Results of management of cervical lymph node metastases in differentiated thyroid carcinoma: Experience in an upper middle-income country.
e18158 Background: Thyroid cancer frequently produces metastases in the central compartment of the neck, followed by the lateral lymph node compartments....
Clinicopathological features and survival outcomes in patients with high microsatellite instability small intestine cancers: A National Cancer Database analysis.
e15726 Background: Small intestine cancer (SIC) is a rare malignancy, accounting for less than 5% of all gastrointestinal cancers. The incidence of SIC ha...
Accelerating treatment decisions with liquid biopsy NGS in non-small cell lung cancer.
e20536 Background: Next Generation Sequencing (NGS) to identify actionable biomarkers has revolutionized non-small cell lung cancer (NSCLC) treatment, thu...
Human compared to AI: A single-blind evaluation of Spanish language translation quality.
e13678 Background: Informed consent forms (ICF) are valuable decision-making aids and information resources for research participants. Regulations require...
Phase II study of disitamab vedotin (RC48) in combination with tislelizumab and bevacizumab in patients (Pts) with HER2 alterations locally advanced or metastatic NSCLC: Primary analysis results of RESOLUTION.
e20515 Background: Antibody-drug conjugates (ADC) have recently revolutionized the treatment of advanced NSCLC. RC48 is a novel ADC that carries a tubulin...
Racial disparities and survival outcomes in secondary acute myeloid leukemia: A SEER-based analysis.
e18540 Background: Secondary Acute Myeloid Leukemia (sAML) comprising AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML), h...
A real-world comparative study of hypertension (HTN) and time to treatment failure (TTF) with acalabrutinib versus ibrutinib in treatment-naive Medicare-eligible patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
e23279 Background: Bruton tyrosine kinase inhibitors (BTKis)are standard of care in CLL/SLL, but are associated with cardiovascular (CV) toxicities, such...
Factors associated with patient-reported outcomes in hospitalized patients with cancer.
11116 Background: Utilization of patient reported outcomes (PROs) in the ambulatory setting can help to improve symptom control and clinical outcomes amon...
Workforce, economic, and infrastructural barriers to global oncology clinical trial participation: Focus on sub-Saharan Africa.
11091 Background: Despite Sub-Saharan Africa's (SSA) growing cancer burden, the region remains grossly underrepresented in global oncology clinical trials...
TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer.
TPS5618 Background: Sacituzumab tirumotecan (sac-TMT; formerly MK-2870/SKB264) is an antibody‒drug conjugate comprising a trophoblast cell-surface antigen...
Investigating the efficacy and safety of ponatinib in acute lymphoblastic leukemia: A systematic review.
e18531 Background: Ponatinib has been well studied in treating Chronic Myeloid Leukemia. However, there are no reviews to date analyzing the efficacy of p...
Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3 <sup>rd</sup> line or greater metastatic pancreatic cancer.
2542 Background: Lymphopenia and high CA19-9 levels are associated with poor prognosis in pancreatic cancer patients. N-803 (ANKTIVA), an IL-15 superagoni...
Effect of cyclin E overexpression on anti-tumor immune responses via activation of the cGAS/STING pathway following radiotherapy.
e15712 Background: Cyclin E is a key regulator of the G1-to-S phase transition and is often upregulated in cancers. Its abnormal activation contributes to...
Influenza and COVID-19 vaccination uptake among cancer survivors in the US.
11085 Background: Cancer survivors are at increased risk of comorbidity and mortality from respiratory viral infections including influenza (flu) and COVI...
Sintilimab in combination with cetuximab and chemotherapy as first-line treatment for RAS/BRAF wild-type advanced colorectal cancer (CALLIOPSIS): An open-label, non-comparative, phase 1b/2 dose escalation and expansion trial.
e15531 Background: Immunotherapy offers limited therapeutic benefit in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Mechanistic studie...
Trends in pancreatic cancer mortality in older adults with diabetes mellitus in the United States (1999–2023).
e16402 Background: Pancreatic cancer, the 3rd leading cause of U.S. cancer deaths, has a 5-year survival rate of 2–11.5% and aggressive progression. Diabe...
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.
1016 Background: In HER2+ advanced breast cancer (ABC), standard treatment has been anti-HER2 therapy with chemotherapy, regardless of hormone receptor st...
Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)–A molecularly selected cooperative group platform study.
5066 Background: PC-BETS registered patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) for circulating tumour (ct)DNA-based genom...
Comparative of PD-L1 expression on live single circulating tumor cells with PD-L1 in tumor tissue assessed by immunohistochemistry in advanced NSCLC patients.
e15070 Background: Live single circulating tumor cells (sCTCs) can provide valuable insights matching or differentiated to tissue biology and real-time dy...